Cerebrolysin (Cerebrolysin)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Nootropics

Included in the formulation
  • Cerebrolysin®
    solution for injections 
    EVER Neuro Pharma GmbH     Austria
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    ONLS

    АТХ:

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:

    It consists of low-molecular biologically active neuropeptides penetrating the blood-brain barrier, where it exerts a multimodal effect on neurons of the brain. It has a neuroprotective effect, possesses a neurotrophic activity.

    It enhances aerobic energy metabolism, improves protein synthesis inside brain cells. Prevents the formation of free radicals, reduces the neurotoxic effect of glutamate.

    It improves cognitive functions, positively influences memorization processes.

    Pharmacokinetics:

    Not described.

    It is known that after a single administration the activity of cerebrolysin in blood plasma persists for 24 hours.

    Indications:

    It is used to treat Alzheimer's disease, dementia syndrome, chronic cerebrovascular insufficiency, ischemic stroke, hyperactivity and attention deficit in children. Used for traumatic injuries of the brain and spinal cord, endogenous depression, resistant to the action of antidepressants.

    ICD-10

    V.F00-F09.F00 *   Dementia in Alzheimer's disease (G30 .- +)

    V.F00-F09.F01   Vascular dementia

    V.F00-F09.F03   Dementia, unspecified

    V.F30-F39.F32   Depressive episode

    V.F30-F39.F33   Recurrent depressive disorder

    V.F70-F79.F79   Mental retardation, unspecified

    V.F90-F98.F90.0   Violation of activity and attention

    VI.G30-G32.G30   Alzheimer's disease

    IX.I60-I69.I63   Cerebral infarction

    IX.I60-I69.I67.2   Cerebral atherosclerosis

    IX.I60-I69.I69   Effects of cerebrovascular disease

    XIX.S00-S09.S06   Intracranial injury

    XIX.T90-T98.T90   Consequences of head injuries

    Contraindications:

    Acute renal failure, epileptic status, individual intolerance.

    Carefully:

    Allergic diathesis.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used in pregnancy and lactation.

    Dosing and Administration:

    Intravenous and intramuscular. The dose is calculated individually.

    The highest daily dose: 50 ml.

    The highest single dose: 50 ml.

    Side effects:

    Central and peripheral nervous system: headache, dizziness, agitation, confusion, insomnia, apathy, tremor.

    Respiratory system: shortness of breath, hyperventilation.

    The cardiovascular system: arterial hypotension or hypertension, with rapid administration - arrhythmia.

    Digestive system: decreased appetite, rarely - vomiting, constipation.

    Dermatological reactions: hyperhidrosis, hyperemia, pruritus.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Strengthens the action of monoamine oxidase inhibitors and antidepressants.

    Special instructions:

    After opening the vial / ampoule with cerebrolysin, the solution must be used immediately.

    Instructions
    Up